Catalog No.
DVV02803
Description
Motavizumab (MEDI-524, NUMAX, NISTmAb) is a second generation monoclonal antibody (mAb) derived from palivizumab (Synagis) using affinity maturation techniques. Motavizumab is currently undergoing US Food and Drug Administration review as a treatment for respiratory syncytial virus (RSV) prophylaxis. It has been evaluated in large-scale clinical studies, and has demonstrated efficacy in reducing the disease burden of RSV in high-risk infant populations.Motavizumab (MEDI-524, NUMAX, NISTmAb) has higher affinity and a longer half-life, was effective in reducing RSV hospitalization in high-risk full-term infants in the US, but was not licensed due to safety concerns (allergic reactions) .
Expression system
Mammalian Cells
Species reactivity
HRSV-A
Host species
Humanized
Isotype
IgG1, kappa
Clonality
Monoclonal
Target
F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1
Concentration
2.8 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P03420
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
MEDI-524,NUMAX, NISTmAb, CR9503, CAS: 677010-34-3
Clone ID
Motavizumab
Motavizumab, PMID: 20065632
Motavizumab for the prevention of respiratory syncytial virus infection in infants, PMID: 19764889
Motavizumab, RSV, and subsequent wheezing, PMID: 27301921
Motavizumab, RSV, and subsequent wheezing - Authors' reply, PMID: 27998592
Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial, PMID: 20008423
Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo, PMID: 29553863
Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness, PMID: 24356256
Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations, PMID: 19330726
Motavizumab, a neutralizing anti-Respiratory Syncytial Virus (Rsv) monoclonal antibody significantly modifies the local and systemic cytokine responses induced by Rsv in the mouse model, PMID: 17961258
Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab, PMID: 17990791
Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial, PMID: 26511956
Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion, PMID: 20519399
A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults, PMID: 24080653
A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease, PMID: 21522037
Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn), PMID: 16793771
Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children, PMID: 19258920
Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection, PMID: 28605249
Structural basis of respiratory syncytial virus neutralization by motavizumab, PMID: 20098425
Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus, PMID: 21549714
A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season, PMID: 20525274
Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children, PMID: 19636278
Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract, PMID: 17362988
Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection, PMID: 25070304
Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab, PMID: 21208913
Computational redesign of human respiratory syncytial virus epitope as therapeutic peptide vaccines against pediatric pneumonia, PMID: 29500665
Evaluation of a synthetic peptide as a replacement for the recombinant fusion protein of respiratory syncytial virus in a potency ELISA, PMID: 20943340
Pharmacological management of human respiratory syncytial virus infection, PMID: 32808830
Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes, PMID: 21613394
[Anti RS virus drugs], PMID: 22568137
The long road to protect infants against severe RSV lower respiratory tract illness, PMID: 31105933
A review of palivizumab and emerging therapies for respiratory syncytial virus, PMID: 21831008
In silico approach towards designing virtual oligopeptides for HRSV, PMID: 25525622
Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review, PMID: 20131925
Respiratory syncytial virus disease: update on treatment and prevention, PMID: 21171875
Letter from the editor, PMID: 20065631
An epitope-specific chemically defined nanoparticle vaccine for respiratory syncytial virus, PMID: 34145291
Evolution of prophylaxis: MoAb, siRNA, vaccine, and small molecules, PMID: 19651397
Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection, PMID: 19562644
Respiratory syncytial virus (RSV) prevention and treatment: past, present, and future, PMID: 19689261
New strategies for control of respiratory syncytial virus infection, PMID: 18978532
Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients, PMID: 22395247
Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children, PMID: 23633336
Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen, PMID: 30789898
Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children, PMID: 29470837
Adeno-Associated Virus Vector-Mediated Expression of Antirespiratory Syncytial Virus Antibody Prevents Infection in Mouse Airways, PMID: 34415793
A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies, PMID: 29541870
An Epitope-Specific Respiratory Syncytial Virus Vaccine Based on an Antibody Scaffold, PMID: 26434555
Induction of high titred, non-neutralising antibodies by self-adjuvanting peptide epitopes derived from the respiratory syncytial virus fusion protein, PMID: 28894111
Characterization of neutralizing affinity-matured human respiratory syncytial virus F binding antibodies in the sub-picomolar affinity range, PMID: 22407977
Respiratory syncytial virus: diagnosis, treatment and prevention, PMID: 23055894
For research use only. Not for human or drug use.
